1
40
3
-
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
February 2024 List
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
Citation List Month
February List 2024
URL Address
<a href="http://doi.org/10.1016/j.arcped.2023.09.014" target="_blank" rel="noreferrer noopener"> http://doi.org/10.1016/j.arcped.2023.09.014</a>
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Withholding life support for children with severe neurological impairment: Prevalence and predictive factors prior to admission in the PICU
Publisher
An entity responsible for making the resource available
Archives de Pediatrie
Date
A point or period of time associated with an event in the lifecycle of the resource
2023
Subject
The topic of the resource
child; article; controlled study; female; human; major clinical study; male; retrospective study; palliative therapy; intensive care unit; assisted ventilation; pediatric intensive care unit; intensive care; therapy; pediatrician; prevalence; functional status; disability; special situation for pharmacovigilance
Creator
An entity primarily responsible for making the resource
Duval C; Porcheret F; Toulouse J; Alexandre M; Roulland C; Viallard ML; Brossier D
Description
An account of the resource
Our study aimed to evaluate the prevalence and predictive factors of withholding life support for children suffering from severe neurological impairment before admission to the pediatric intensive care unit (PICU). Method: Children under 18 years of age with severe neurological impairment, who were hospitalized between January 2006 and December 2016, were included in this retrospective study. They were allocated to a withholding group or a control group, depending on whether life support was withheld or not, before admission to the PICU. Results: Overall, 119 patients were included. At admission to the PICU, the rate of withholding life support was 10 % (n = 12). Predictive factors were: (1) a previous stay in the PICU (n = 11; 92 %, p<0.01, odds ratio [OR]: 14 [2-635], p = 0.001); (2) the need for respiratory support (n = 5; 42 %, p = 0.01, OR: 6 [1-27], p = 0.01); (3) the need for feeding support (n = 10; 83 %, p = 0.01, OR: 10 [2-100], p = 0.001); and (4) a higher functional status score (FSS: 16 [12.5-19] vs. 10 [8-13], p<0.01). Conclusion: The withholding of life support for children suffering from severe neurological impairment appeared limited in our pediatric department. The main predictor was at least one admission to the PICU, which raised the question of the pediatrician's role in the decision to withhold life support.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1016/j.arcped.2023.09.014" target="_blank" rel="noreferrer noopener">10.1016/j.arcped.2023.09.014</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. PedPalASCNET does not hold any rights over the resource listed here. All rights are retained by the journal listed under publisher and/or the creator(s).
2023
Alexandre M
Archives de Pediatrie
Article
assisted ventilation
Brossier D
Child
Controlled Study
Disability
Duval C
February List 2024
Female
Functional Status
Human
Intensive Care
Intensive Care Unit
Major Clinical Study
Male
Palliative Therapy
Pediatric Intensive Care Unit
Pediatrician
Porcheret F
Prevalence
Retrospective Study
Roulland C
special situation for pharmacovigilance
Therapy
Toulouse J
Viallard ML
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
Citation List Month
November 2017 List
Notes
<p>1557-8240<br />Heneghan, Julia A<br />Pollack, Murray M<br />Journal Article<br />Review<br />United States<br />Pediatr Clin North Am. 2017 Oct;64(5):1147-1165. doi: 10.1016/j.pcl.2017.06.011.</p>
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Morbidity: Changing the Outcome Paradigm for Pediatric Critical Care
Publisher
An entity responsible for making the resource available
Pediatric Clinics Of North America
Date
A point or period of time associated with an event in the lifecycle of the resource
2017
Subject
The topic of the resource
Critical Care; Functional Status; Morbidity; Outcomes; Outcomes Research; Pediatric Critical Care; Pediatric Intensive Care; Quality
Creator
An entity primarily responsible for making the resource
Heneghan JA; Pollack M
Description
An account of the resource
The focus of critical care has evolved from saving lives to preservation of function. Morbidity rates in pediatric critical care are approximately double mortality rates. Morbidity includes complications of disease and medical care. In pediatric critical care, functional status morbidity is an intermediate outcome in the progression toward death and is the result of the same factors associated with mortality, including physiologic profiles and case-mix factors. The Functional Status Scale developed by Collaborative Pediatric Critical Care Research Network is a validated, granular, age-independent measure of functional status that has proved valuable and practical even in large outcome studies.
Identifier
An unambiguous reference to the resource within a given context
10.1016/j.pcl.2017.06.011
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. PedPalASCNET does not hold any rights over the resource listed here. All rights are retained by the journal listed under publisher and/or the creator(s).
2017
Critical Care
Functional Status
Heneghan JA
Morbidity
November 2017 List
Outcomes
Outcomes Research
Pediatric Clinics of North America
Pediatric Critical Care
Pediatric Intensive Care
Pollack M
Quality
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
Citation List Month
September 2017 List
Notes
<p>Using Smart Source Parsing ( (no pagination), 2015. Article Number: CD010750. Date of Publication: Mar 2015</p>
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Pharmacological Interventions For Pain In Children And Adolescents With Life-limiting Conditions
Publisher
An entity responsible for making the resource available
Cochrane Database Of Systematic Reviews
Date
A point or period of time associated with an event in the lifecycle of the resource
2017
Subject
The topic of the resource
Drug Efficacy; Neuropathic Pain/dt [drug Therapy]; Nociceptive Pain/dt [drug Therapy]; 52-26-6 (morphine); 57-27-2 (morphine); 73-78-9 (lidocaine); 76-42-6 (oxycodone); 76-57-3 (codeine); 76-99-3 (methadone); 94-09-7 (benzocaine); 94-24-6 (tetracaine); 103-90-2 (paracetamol); 124-90-3 (oxycodone); 125-56-4 (methadone); 133-16-4 (chloroprocaine); 136-47-0 (tetracaine); 137-58-6 (lidocaine); 297-88-1 (methadone); 437-38-7 (fentanyl); 1095-90-5 (methadone); 1134-47-0 (baclofen); 1333-08-0 (benzocaine); 2180-92-9 (bupivacaine); 3858-89-7 (chloroprocaine); 15307-79-6 (diclofenac); 15307-86-5 (diclofenac); 15687-27-1 (ibuprofen); 18010-40-7 (bupivacaine); 23142-53-2 (methadone); 24847-67-4 (lidocaine); 31121-93-4 (ibuprofen); 38396-39-3 (bupivacaine); 40391-99-9 (pamidronic Acid); 52485-79-7 (buprenorphine); 53152-21-9 (buprenorphine); 55750-21-5 (bupivacaine); 56934-02-2 (lidocaine); 57248-88-1 (pamidronic Acid); 66376-36-1 (alendronic Acid); 74103-06-3 (ketorolac); 79261-49-7 (ibuprofen); 527688-20-6 (ibuprofen); Alendronic Acid/ct [clinical Trial]; Alendronic Acid/dt [drug Therapy]; Analgesia; Baclofen/ct [clinical Trial]; Baclofen/dt [drug Therapy]; Benzocaine/ct [clinical Trial]; Benzocaine/dt [drug Therapy]; Bupivacaine/ct [clinical Trial]; Bupivacaine/dt [drug Therapy]; Buprenorphine/ct [clinical Trial]; Buprenorphine/dt [drug Therapy]; Cerebral Palsy; Chloroprocaine/ct [clinical Trial]; Chloroprocaine/dt [drug Therapy]; Codeine/ct [clinical Trial]; Codeine/dt [drug Therapy]; Diclofenac/ct [clinical Trial]; Diclofenac/dt [drug Therapy]; Drug Clearance; Drug Safety; Fentanyl/ct [clinical Trial]; Fentanyl/dt [drug Therapy]; Functional Status; Human; Ibuprofen/ct [clinical Trial]; Ibuprofen/dt [drug Therapy]; Ketorolac/ct [clinical Trial]; Ketorolac/dt [drug Therapy]; Length Of Stay; Lidocaine/ct [clinical Trial]; Lidocaine/dt [drug Therapy]; Methadone/ct [clinical Trial]; Methadone/dt [drug Therapy]; Morphine/ct [clinical Trial]; Morphine/dt [drug Therapy]; Neuropathic Pain/dt [drug Therapy]; Nociceptive Pain/dt [drug Therapy]; Osteogenesis Imperfecta; Oxycodone/ct [clinical Trial]; Oxycodone/dt [drug Therapy]; Pain Intensity; Pain Severity; Pamidronic Acid/ct [clinical Trial]; Pamidronic Acid/dt [drug Therapy]; Paracetamol/ct [clinical Trial]; Paracetamol/dt [drug Therapy]; Priority Journal; Psychological Well-being; Quality Of Life; Randomized Controlled Trial (topic); Review; Risk Benefit Analysis; Tetracaine/ct [clinical Trial]; Tetracaine/dt [drug Therapy]; Treatment Outcome
Creator
An entity primarily responsible for making the resource
Beecham E; Candy B; Howard R; McCulloch R; Laddie J; Rees H; Vickerstaff V; Bluebond-Langner M; Jones L
Description
An account of the resource
Background: Pain is one of the most common symptoms in children and young people (CYP) with life-limiting conditions (LLCs) which include a wide range of diagnoses including cancer. The current literature indicates that pain is not well managed, however the evidence base to guide clinicians is limited. There is a clear need for evidence from a systematic review to inform prescribing. Objectives: To evaluate the evidence on the effectiveness of different pharmacological interventions used for pain in CYP with LLCs. Search methods: The following electronic databases were searched up to December 2014: CENTRAL (in the Cochrane Library), MEDLINE, EMBASE, PsycINFO and CINAHL. In addition, we searched conference proceedings and reference lists of included studies. For completeness, we also contacted experts in the field. No language restrictions were applied. Selection criteria: Randomised controlled trials (RCTs), quasi-randomised studies and other studies that included a clearly defined comparator group were included. The studies investigated pharmacological treatments for pain associated with LLCs in CYP. The treatment included those specifically developed to treat pain and those that acted as an adjuvant, where the treatment was not primarily developed to treat pain but has pain relieving properties. The LLC was identified by its inclusion in the Richard Hain Directory of LLCs. Data collection and analysis: Citations were screened by five review authors. Data were extracted by one review author and checked by a second. Two review authors assessed the risk of bias of included studies. A sufficient number of studies using homogeneous outcomes was not identified so a meta-analysis was not possible. Main results: We identified 24,704 citations from our database search. Nine trials with 379 participants fulfilled our inclusion criteria. Participants had cerebral palsy (CP) in five of the studies and osteogenesis imperfecta (OI) in the other four. Participants across the trials ranged in age from 2 to 19 years. All studies, apart from one cross-over trial, were parallel designed RCTs. Three of the trials on CP evaluated intrathecal baclofen (ITB) and two botulinum toxin A (BoNT-A). All of the OI trials evaluated the use of bisphosphonates (two alendronate and one pamidronate). No trials were identified that evaluated a commonly used analgesic in this patient group. Pain was a secondary outcome in five of the eight identified studies. Overall the quality of the trials was mixed. Only one study involved over 100 participants. For the two ITB studies for pain in CP, in the same study population but assessed at different time points in their disease, both found an effect on pain favouring the intervention compared to the control group (standard care or placebo) (mean difference (MD) 4.20, 95% confidence interval (CI) 2.15 to 6.25; MD 26.60, 95% CI 2.61 to 50.59, respectively). In these studies most of the adverse events related to the procedure or device for administration rather than the drug, such as swelling at the pump site. In one trial there were also eight serious adverse effects; these included difficulty swallowing and an epileptic seizure. The trial did not state if these occurred in the intervention group. At follow-up in both BoNT-A trials there was no evidence of a difference in pain between the trial arms among CP participants. The adverse events in the BoNT-A trials mostly involved those who received the intervention drug and involved seizures. Gastrointestinal problems were the most frequent adverse event in those who received alendronate. The trial investigating pamidronate found no evidence of a difference in pain compared to the control group. No adverse events were reported in this trial. Authors' conclusions: Published, controlled evidence on the pharmacological interventions for pain in CYP with LLCs is limited. The evidence that is currently available evaluated pain largely as a secondary outcome and the drugs used were all adjuvants and not always commonly used in general paediatric palliative care for p
Identifier
An unambiguous reference to the resource within a given context
10.1002/14651858.CD010750.pub2
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. PedPalASCNET does not hold any rights over the resource listed here. All rights are retained by the journal listed under publisher and/or the creator(s).
103-90-2 (paracetamol)
1095-90-5 (methadone)
1134-47-0 (baclofen)
124-90-3 (oxycodone)
125-56-4 (methadone)
133-16-4 (chloroprocaine)
1333-08-0 (benzocaine)
136-47-0 (tetracaine)
137-58-6 (lidocaine)
15307-79-6 (diclofenac)
15307-86-5 (diclofenac)
15687-27-1 (ibuprofen)
18010-40-7 (bupivacaine)
2017
2180-92-9 (bupivacaine)
23142-53-2 (methadone)
24847-67-4 (lidocaine)
297-88-1 (methadone)
31121-93-4 (ibuprofen)
38396-39-3 (bupivacaine)
3858-89-7 (chloroprocaine)
40391-99-9 (pamidronic Acid)
437-38-7 (fentanyl)
52-26-6 (morphine)
52485-79-7 (buprenorphine)
527688-20-6 (ibuprofen)
53152-21-9 (buprenorphine)
55750-21-5 (bupivacaine)
56934-02-2 (lidocaine)
57-27-2 (morphine)
57248-88-1 (pamidronic Acid)
66376-36-1 (alendronic Acid)
73-78-9 (lidocaine)
74103-06-3 (ketorolac)
76-42-6 (oxycodone)
76-57-3 (codeine)
76-99-3 (methadone)
79261-49-7 (ibuprofen)
94-09-7 (benzocaine)
94-24-6 (tetracaine)
Alendronic Acid/ct [clinical Trial]
Alendronic Acid/dt [drug Therapy]
Analgesia
Baclofen/ct [clinical Trial]
Baclofen/dt [drug Therapy]
Beecham E
Benzocaine/ct [clinical Trial]
Benzocaine/dt [drug Therapy]
Bluebond-Langner M
Bupivacaine/ct [clinical Trial]
Bupivacaine/dt [drug Therapy]
Buprenorphine/ct [clinical Trial]
Buprenorphine/dt [drug Therapy]
Candy B
Cerebral Palsy
Chloroprocaine/ct [clinical Trial]
Chloroprocaine/dt [drug Therapy]
Cochrane Database of Systematic Reviews
Codeine/ct [clinical Trial]
Codeine/dt [drug Therapy]
Diclofenac/ct [clinical Trial]
Diclofenac/dt [drug Therapy]
Drug Clearance
Drug Efficacy
Drug Safety
Fentanyl/ct [clinical Trial]
Fentanyl/dt [drug Therapy]
Functional Status
Howard R
Human
Ibuprofen/ct [clinical Trial]
Ibuprofen/dt [drug Therapy]
Jones L
Ketorolac/ct [clinical Trial]
Ketorolac/dt [drug Therapy]
Laddie J
Length Of Stay
Lidocaine/ct [clinical Trial]
Lidocaine/dt [drug Therapy]
McCulloch R
Methadone/ct [clinical Trial]
Methadone/dt [drug Therapy]
Morphine/ct [clinical Trial]
Morphine/dt [drug Therapy]
Neuropathic Pain/dt [drug Therapy]
Nociceptive Pain/dt [drug Therapy]
Osteogenesis Imperfecta
Oxycodone/ct [clinical Trial]
Oxycodone/dt [drug Therapy]
Pain Intensity
Pain Severity
Pamidronic Acid/ct [clinical Trial]
Pamidronic Acid/dt [drug Therapy]
Paracetamol/ct [clinical Trial]
Paracetamol/dt [drug Therapy]
Priority Journal
Psychological Well-being
Quality Of Life
Randomized Controlled Trial (topic)
Rees H
Review
Risk Benefit Analysis
September 2017 List
Tetracaine/ct [clinical Trial]
Tetracaine/dt [drug Therapy]
Treatment Outcome
Vickerstaff V